UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | I | J | K | L | M | N | R | S | T | U | V | W
Number of items: 108.

A

Ah-See, MLW; Makris, A; Burcombe, RJ; Davies, C; Cladd, HJ; Padhani, AR; Harris, AL; (2003) Evaluation of plasma & serum vascular endothelial growth factor (VEGF) during neoadjuvant chemotherapy for primary breast cancer. British Journal of Cancer , 88 S44-S44.

Ah-See, MLW; Taylor, NJ; Makris, A; Burcombe, RJ; Stirling, JJ; Cladd, HJ; Leach, MO; (2003) Valuation of multi-functional dynamic contrast-enhanced MRI to predict response to neoadjuvant chemotherapy in primary breast cancer. British Journal of Cancer , 88 S41-S41.

Ahmedzai, S; Hoskin, PJ; (2003) Assessment and management of malignant disease. In: Muers, MF, (ed.) Oxford Textbook: Supportive Care in Respiratory Disease. Oxford University Press: Oxford.

Ameer-Beg, SM; Edme, N; Peter, M; Barber, PR; Ng, T; Vojnovic, B; (2003) Imaging protein-protein interactions by multiphoton FLIM. Proceedings of SPIE - The International Society for Optical Engineering , 5139 pp. 180-189.

Ann, F; (2003) Thalidomide: horror and redemption. Cancer Nursing Practice , 2 (25) pp. 10-12.

Arkenau, HT; Kruse, F; Jend, HH; Porschen, R; (2003) Differential diagnosis of Morbus Crohns disease: Intussusception of the colon. Zeitschrift fur Gastroenterologie , 41 (7) pp. 663-666. 10.1055/s-2003-40549.

Assersohn, L; Salter, J; Powles, TJ; A'Hern, R; Makris, A; Gregory, RK; Chang, J; (2003) Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Research and Treatment , 82 (2) pp. 113-123.

B

BBC, NO; (2003) Blood test spots 'asbestos cancer'. UNSPECIFIED

BBC, NO; (2003) Scans help spot lung cancer early. UNSPECIFIED

BBC, NO; (2003) Thalidomide trials to fight cancer. UNSPECIFIED

BBC, NO; (2003) Warning to heed lung cancer signs. UNSPECIFIED

BBC, R4; (2003) Thalidomide Trial. UNSPECIFIED

Beresford, M; Glynne-Jones, R; Makris, A; Harrison, M; (2003) Lymph node staging following preoperative chemoradiation in rectal cancer. British Journal of Cancer , 88 S21-S21.

Braithwaite, D; Sutton, S; Mackay, J; Stein, J; Hopkinson, I; Emery, J; (2003) UNSPECIFIED In: (Proceedings) 'Computer support for genetic risk assessment and advice about breast cancer susceptibility: a feasibility study of patient self-assessment in a family history clinic'. In AACR Frontiers in Cancer Prevention, Phoenix, Arizona, 26-30 October.

Brookman-Amissah, N; Price, RK; Foxon, R; Mackay, A; O'Hare, MJ; Stein, RC; (2003) The effects of estradiol and ICI 182,780 treatment of primary breast cancer cells on gene transcription and comparison to effects in established cell lines. In: (Proceedings) British Cancer Research Meeting 2003. (pp. S49-S49). NATURE PUBLISHING GROUP

C

Calvert, H; (2003) Developing drugs for cancer: Striking balance between clinical pragmatism and scientific allure. In: BRITISH JOURNAL OF CANCER. (pp. S7 - S7). NATURE PUBLISHING GROUP

Carnell, D; Smith, R; Taylor, J; Stirling, J; Hoskin, P; Padhani, A; (2003) Evaluation of hypoxia within human prostate carcinoma using quantified bold MRI and pimonidazole immunohistochemical mapping. British Journal of Cancer , 88 S12-S12.

Carnell, DM; Daley, FM; Smith, RE; Hoskin, P; Murray, GI; Everett, SA; (2003) CYP1B1 protein expression in prostate carcinoma. British Journal of Cancer , 88 S34-S34.

Catherine, E; (2003) Thalidomide used in trials to cure cancer. Camden New Journal 25-.

Clingen, PH; DeSilva, IU; Ghadessy, FJ; Thurston, DE; Hartley, JA; (2003) The role of nucleotide excision repair and homologous recombination in the sensitivity of mammalian cells to the minor groove crosslinking pyrrolo[2,1-c][1,4]benzodiazepine dimmer SJG-136(NSC694501). In: (pp. 2672-).

Corrie, P; Spanswick, VJ; Sehmbi, R; Jonson, A; Shaw, J; Dowen, S; Biswas, S; ... Hartley, JA; + view all (2003) Increased persistence of treosulfan-induced DNA interstrand crosslinks when combined with gemcitabine: Proof of principle within a phase I trial. In: (pp. 128-).

D

Daly, ME; Makris, A; Reed, M; Lewis, CE; (2003) Hemostatic regulators of tumor angiogenesis: A source of antiangiogenic agents for cancer treatment? Journal of the National Cancer Institute , 95 (22) pp. 1660-1673.

Dangoor, A; Ranson, M; Lee, SM; Beech, J; Sherlock, DJ; Wilkinson, PM; Valle, JW; (2003) Treatment of inoperable hepatocellular carcinoma (HCC) with pegylated liposomal doxorubicin (Caelyx). In: (Proceedings) 2003 ASCO Annual Meeting/39th Annual Meeting, Chicago, Illinois.. (pp. 361-). Proceedings of the American Society of Clinical Oncology

David, F; (2003) Birth defects drug is poised for comeback. Financial Times

Davis, AM; Dische, S; Gerber, L; Saunders, M; Leung, SF; O'Sullivan, B; (2003) Measuring postirradiation subcutaneous soft-tissue fibrosis: State-of-the-art and future directions. Seminars in Radiation Oncology , 13 (3) pp. 203-213.

DeCanha, S; Hoskin, PJ; (2003) Current thinking of the role of radiotherapy in metastatic disease. In: Miles, A, (ed.) Key Advances in the effective Management of Breast Cancer. Royal College of Physicians: London.

Dische, S; Saunders, MI; (2003) Complexity and simplicity in the measurement and recording of the adverse effects of cancer treatment. Radiotherapy And Oncology , 66 (3) pp. 249-251.

E

Eccersley, AJ; Wilson, EM; Makris, A; Novell, JR; (2003) Referral guidelines for colorectal cancer - do they work? Annals of the Royal College of Surgeons of England , 85 (2) pp. 107-110.

F

Flynn, AA; Pedley, RB; Green, AJ; Dearling, JL; El-Emir, E; Boxer, GM; Boden, R; (2003) The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. RADIAT RES , 159 (2) 182 - 189.

Friedmann, BJ; Caplin, M; Hartley, JA; Hochhauser, D; (2003) UNSPECIFIED In: (Proceedings) Modulation of the activity of chemotherapeutic agents by the epidermal growth factor inhibitor gefitinib ('Iressa', ZD1839). Clinical Cancer Research

Friedmann, BJ; Caplin, M; Hartley, JA; Hochhauser, D; (2003) Modulation of the activity of chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib ('Iressa', ZD1839) in human cancer cell lines. In: CLINICAL CANCER RESEARCH. (pp. 6094S - 6094S). AMER ASSOC CANCER RESEARCH

G

Grigg, A; Solal-Celigny, P; Hoskin, P; Taylor, K; McMillan, A; Forstpointner, R; Bacon, P; ... Hiddemann, W; + view all (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leukemia and Lymphoma , 44 (9) pp. 1503-1508.

H

Harney, J; Goodchild, K; Phillips, H; Glynne-Jones, R; Hoskin, PJ; Saunders, MI; (2003) A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. Clinical Oncology , 15 (3) pp. 109-114.

Harney, J; Shah, N; Short, S; Saunders, M; Joiner, M; (2003) Low dose hyper-radiosensitivity-a clinical assessment. In: (pp. Abs 173-).

Hoskin, PJ; (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treatment Reviews , 29 (4) pp. 321-327.

Hoskin, PJ; (2003) Case selection in the management of cerebral metastases. Clinical Oncology , 15 (7) pp. 420-421.

Hoskin, PJ; (2003) What are the oncologist's need. European Journal of Nuclear Medicine and Molecular Imaging , 30 (S1) S37-S41. 10.1007/s00259-003-1158-5.

Hoskin, PJ; (2003) Radiotherapy in symptom management. In: Doyle, D and Hanks, GW and Cherny, N and Calman, K, (eds.) Oxford Textbook of Palliative Care. Oxford University Press.: Oxford.

Hoskin, PJ; (2003) Evaluation and management of the patient with bone metastases at presentation. In: Jasmin, C and Caanna, R and Coia, L and Coleman, R and Diel, I, (eds.) Textbook of Bone Metastases. Wiley: Chichester.

Hoskin, PJ; Bownes, PJ; Ostler, P; Walker, K; Bryant, L; (2003) High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiotherapy And Oncology , 68 (3) pp. 285-288.

Hoskin, PJ; Grover, A; Bhana, R; (2003) Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. Radiotherapy And Oncology , 68 (2) pp. 175-180.

Hoskin, PJ; O'Doherty, MJ; (2003) Lymphoma: Diagnosis and Management. European Journal Of Nuclear Medicine and Molecular Imaging , 30 (S1) BP87-BP98. 10.1007/s00259-003-1342-7.

Hoskin, PJ; Sibtain, A; Daley, FM; Wilson, GD; (2003) GLUTI and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. British Journal of Cancer , 89 (7) pp. 1290-1297. 10.1038/sj.bjc.6601260.

Howie, AJ; Turhan, N; Adu, D; (2003) Powerful morphometric indicator of prognosis in lupus nephritis. QJM , 96 (6) pp. 411-420. 10.1097/01.TP.0000120177.44144.FF.

Huhalov, A; Spencer, DI; Chester, KA; (2003) Mapping Antibody:Antigen Interactions by Mass Spectrometry and Bioinformatics. In: Lo, BKC, (ed.) Antibody Engineering Methods and Protocols. (pp. 465-480). Humana Press

I

Irwin, HL; Corcoran, F; Boxer, GM; Pedley, RB; Dearling, J; Hartley, JM; Begent, RHJ; (2003) Isolation of tumour cells from peripheral blood for potential assessment of response to antibody directed enzyme prodrug therapy (ADEPT). British Journal of Cancer , 88 S37-S37.

J

Jacqui, T; (2003) Thalidomide used to fight lung cancer. ‘Deformity’ drug in new trial. The Sun 16-.

James, L; Lee, SM; (2003) A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC). In: (Proceedings) 10th World Conference on Lung Cancer, Vancouver.. (pp. S183-). Lung Cancer

James, M; (2003) Lung cancer curbed in thalidomide trial. The Guardian

John, G; (2003) Thalidomide. An unlikely cure? Guardian 60-.

John, T; Ottley, C; Pearson, G; Nowell, G; Calvert, H; Tilby, M; (2003) Sensitive determination of BBR 3464 and cisplatin DNA adduct levels in clinical samples using ICP-MS and PIMMS. In: BRITISH JOURNAL OF CANCER. (pp. S42 - S42). NATURE PUBLISHING GROUP

K

Kalra, D; Singleton, P; Ingram, D; Milan, J; Mackay, J; Detmer, D; Rector, A; (2003) Security and confidentiality approach for the Clinical E-Science Framework (CLEF). In: Cox, S, (ed.) Proceedings of UK e-Science All Hands Meeting 2003. (pp. 825-832). Engineering and Physical Sciences Research Council (EPSRC)

Kate, N; (2003) Bag Drug Makes Good. TIME Magazine 59-.

Kauppila, S; Maaty, WSA; Chen, P; Tomar, RS; Eby, MT; Chapo, J; Chew, S; ... Chaudhary, PM; + view all (2003) Eiger and its receptor, Wengen, comprise a TNF-like system in Drosophila. Oncogene , 22 (31) pp. 4860-4867. 10.1038/sj.onc.1206715.

Keshtgar, MR; Stein, RC; (2003) Breast cancer. [Book]. Patient's pictures. (1st ed.). Health Press Limited: Oxford.

Khalil, AA; Bentzen, SM; Bernier, J; Saunders, MI; Horiot, JC; Van Den Bogaert, W; Cummings, BJ; (2003) Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. International Journal of Radiation Oncology Biology Physics , 55 (3) pp. 568-575.

Kotecha, MT; Hercus, L; Lees, SM; Hartley, JA; Hochhauser, D; (2003) Modulation of topoisomerase Iia expression by sequence specific polyamides. In: (pp. 6539-).

Krause, M; Hessel, F; Wohlfarth, J; Zips, D; Hoinkis, C; Foest, H; Short, S; ... Baumann, M; + view all (2003) Ultrafractionation in A7 malignant glioma in nude mice. pp. 377-383.

Kristeleit, RS; Stimson, L; Workman, P; Aherne, GW; (2003) Effects of the hydroxamic acid histone deacetylase inhibitors trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA) and LAQ824 on histone and protein acetylation. In: CLINICAL CANCER RESEARCH. (pp. 6107S - 6107S). AMER ASSOC CANCER RESEARCH

L

Lacombe, D; Butler-Smith, A; Therasse, P; Fumoleau, P; Burtles, S; Calvert, H; Marsoni, S; ... Verweij, J; + view all (2003) Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network. CANCER INVEST , 21 (1) 137 - 147. 10.1081/CNV-120016408.

Leverrier, Y; Okkenhaug, K; Sawyer, C; Bilancio, A; Vanhaesebroeck, B; Ridley, AJ; (2003) Class I phosphoinositide 3-kinase p110 beta is required for apoptotic cell and Fc gamma receptor-mediated phagocytosis by macrophages. JOURNAL OF BIOLOGICAL CHEMISTRY , 278 (40) pp. 38437-38442. 10.1074/jbc.M306649200. Gold open access

Leverrier, Y; Okkenhaug, K; Sawyer, C; Bilancio, A; Vanhaesebroeck, B; Ridley, AJ; (2003) Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem , 278 (40) 38437 - 38442. 10.1074/jbc.M306649200. Gold open access

Lewis, I; Nooij, M; Whelan, J; Casak, S; Memon, M; Taminiau, A; Hogendoorn, P; ... Intergroup, AKOBOTEO; + view all (2003) Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: A randomised controlled trial of the European Osteosarcoma Intergroup (ISRCTN 86294690). In:

Lyn, BE; Wilson, EM; Williams, FJ; Saunders, MI; Phillips, H; (2003) Chart to Chartwel to Chemotherapy and Chartwel in Non-Small Cell Lung Cancer. British Journal of Cancer , 88 S23-S23.

M

Mackay, HJ; O'Brien, M; Hill, S; Lee, SM; Thatcher, N; Smith, IE; Dunlop, DJ; (2003) A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer. Clinical Oncology , 15 (4) pp. 181-185.

Madhusudan, S; Braybrooke, JP; Forster, M; Wilner, S; Han, C; Kaur, K; Balkwill, F; ... Harris, AL; + view all (2003) A phase II Trial of etanercept a recombinant human soluble tumour necrosis factor receptor (p75) fusion protein in patients with metastatic breast cancer. In: (Proceedings) AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. (pp. 6192S-6192S). AMER ASSOC CANCER RESEARCH

Makris, A; (2003) Critical commentary of: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin and flourouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer:an EORTC-NCIC-SAKK multicenter study. Women's Oncology Review , 3 pp. 237-238.

Martin, F; Chowdhury, S; Neil, SJ; Chester, KA; Cosset, FL; Collins, MK; (2003) Targeted retroviral infection of tumor cells by receptor cooperation. J VIROL , 77 (4) 2753 - 2756. 10.1128/JVI.77.4.2753-2756.2003.

Meyer, T; McTiernan, A; Whelan, J; (2003) A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours. Sarcoma , 7 (1) pp. 13-17. 10.1080/1357714031000114192. Gold open access

Morton, PE; Ng, TC; Roberts, SA; Vojnovic, B; Ameer-Beg, SM; (2003) Time resolved multiphoton imaging of the interaction between the PKC and NFκB signalling pathways. Proceedings of SPIE - The International Society for Optical Engineering , 5139 pp. 216-222.

Murphy, DM; Dolbear, C; Moller, H; Whelan, JS; Pinkerton, CR; (2003) The incidence of cancer in adolescents and young adults in south east England: an analysis of Thames Cancer Registry data 1998-2000. In:

N

Nathan, PD; Hochhauser, D; (2003) Pathogenesis of Cancer. In: Kirk, RM and Ribbans, WJ, (eds.) Clinical Surgery in General. Charchill Livingstone: London.

Nooij, M; Lewis, I; Whelan, JS; Casak, S; Memon, M; Hogendoorn, P; Weeden, S; ... Kirkpatrick, A; + view all (2003) Does increasing dose intensity in patients with operable osteosarcoma of the extremity improve outcome? A randomised controlled trial of the European Osteosarcoma Intergroup (EOI). In:

R

Redpath, JL; Short, SC; Woodcock, M; Johnston, P; (2003) Low dose reduction in transformation frequency compared to unirradiated controls: the role of hyper-radiosensitivity. Radiation Research , 159 pp. 433-436.

Reigner, B; Watanabe, T; Schuller, J; Lucraft, H; Sasaki, Y; Bridgewater, J; Saeki, T; ... Grange, S; + view all (2003) Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY , 52 (3) pp. 193-201. 10.1007/s00280-003-0642-8.

Richards, M; Ponder, M; Everest, S; Pharoah, P; Mackay, J; (2003) Issues of consent and feedback in a genetic epidemiological study of women with breast cancer. Journal of Medical Ethics , 29 pp. 93-96.

Rob, B; (2003) Controversial drug in lung cancer trials. Highbury & Islington Express

Roos, DE; Davis, SR; Turner, SL; O'Brien, PC; Spry, NA; Burmeister, BH; Hoskin, PJ; (2003) Quality assurance experience with the randomized neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05). Radiotherapy And Oncology , 67 (2) pp. 207-212.

S

Sarker, D; Thirlwell, C; Nelson, M; Gazzard, B; Bower, M; (2003) Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS , 17 (6) 861 - 865. 10.1097/01.aids.0000050863.71999.f8.

Sarker, D; Williams, MT; Buscombe, J; Caplin, M; Hochhauser, D; Begent, R; Meyer, T; (2003) Streptozocin, 5-fluorouracil/folinic acid and cisplatin (FCiSt) for advanced neuroendocrine tumours. British Journal of Cancer , 88 S65-S65.

Sarker, D; Williams, MT; Buscombe, J; Caplin, M; Hochhauser, D; Begent, R; Meyer, T; (2003) Streptozocin, 5-fluorouracil/folinic acid and cisplatin (FCiSt) for advanced neuroendocrine tumours. In: (Proceedings) British Cancer Research Meeting 2003. (pp. S65-S65). NATURE PUBLISHING GROUP

Saunders, M; Palmer, AM; Millard, RK; Preece, AW; (2003) Doses to fetal and maternal organs from intravenous (FeCl3)-Fe- 59 or (CoCl2)-Co-57. Radiation Protection Dosimetry , 106 (1) pp. 63-69.

Sharma, SK; Pedley, RB; Irwin, HL; El Emir, E; Boxer, GM; Boden, RW; Chester, KA; (2003) The effect of ADEPT, as a single or combined therapy, in two colorectal xenografts. In: (pp. S37-S37).

Short, S; (2003) UNSPECIFIED In: (Proceedings) 2nd International Conference on Translational Research in Radiation Oncology.

Short, S; (2003) External beam and conformal radiotherapy in the management of gliomas. In: Westphal, , (ed.) Local therapies for glioma. Springer

Short, S; Buffa, F; Bourne, S; Johnston, P; Bentzen, S; (2003) Determining dose response relationships of gene expression in human tumour cells after low radiation doses using micro-array analysis. In:

Short, S; C, B; F, B; S, J; P, B; S, M; (2003) UNSPECIFIED In: (Proceedings) EU-US Molecular Signatures of DNA Damage Workshop.

Short, S; C, H; J, ; (2003) Radiobiology and vascular targeting in glioma. Current opinion in neurology , 16 pp. 651-655.

Sibtain, A; Saunders, MI; Bentzen, SM; Hoskin, PJ; (2003) Pre-treatment Haemoglobin Concentration in Accelerated and Conventional Radiotherapy for Non-small Cell Lung Carcinoma. Clinical Oncology , 16 pp. 58-62.

Strauss, SJ; Marples, M; Napier, MP; Meyer, T; Boxall, J; Rustin, GJS; (2003) A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. Br J Cancer , 89 (10) pp. 1901-1905. 10.1038/sj.bjc.6601414.

Strauss, SJ; McTiernan, A; Driver, D; Hall-Craggs, M; Sandison, A; Cassoni, AM; Kilby, A; ... Whelan, JS; + view all (2003) Single center experience of a new intensive induction therapy for Ewing's family of tumors: Feasibility, toxicity, and stem cell mobilization properties. Journal of Clinical Oncology , 21 (15) pp. 2974-2981. 10.1200/JCO.2003.04.106.

Strauss, SJ; McTiernan, A; Driver, D; Hall-Craggs, M; Sandison, A; Cassoni, AM; Kilby, A; ... Whelan, JS; + view all (2003) Single center experience of a new intensive induction therapy for Ewing's family of tumors: Feasibility, toxicity, and stem cell mobilization properties. J CLIN ONCOL , 21 (15) 2974 - 2981. 10.1200/JCO.2003.04.106.

T

The, T; (2003) Conditions: Lung Cancer.

Thirlwell, C; Brock, CS; (2003) Emergencies in oncology. CLIN MED , 3 (4) 306 - 310.

Tischkowitz, M; Pharoah, P; Mackay, J; (2003) Genetic Susceptibility to Ovarian cancer; Molecular and Clinical Aspects. In: Gore, M and Kehoe, S and Ledermann, J and Miles, A, (eds.) Key Advances in the Effective Management of Ovarian Cancer. Aesculapius: London.

Turner, NC; Hochhauser, D; (2003) New Targets in oesophagogastric cancer. In: Key Advances in Clinical Practice: The Effective Management of Oesophagogastric Cancer. Aesculapius Press

U

UCL, PA; (2003) Scans help spot lung cancer early. 29-.

V

Vassileva, VT; (2003) Analysis of Genetic Targets Contributing to Mutator Phenotype of Endometrial Cancer. Masters thesis , University of Toronto.

Venables, K; Winfield, EA; Aird, EGA; Hoskin, PJ; (2003) Three-dimensional distribution of radiation within the breast: An intercomparison of departments participating in the start trial of breast radiotherapy fractionation. International Journal of Radiation Oncology Biology Physics , 55 (1) pp. 271-279.

W

Wells, G; Gale, T; Hardy, A; Hamaguchi, A; Hartley, JA; Wilkinson, GP; Loadman, P; ... Thurston, DE; + view all (2003) Pyrrolobenzodiazepine-polyamide libraries:synthesis and DNA binding selectivity. Proceeding of the American Association for Cancer Research. In: (pp. 452-).

Westbury, CB; Harrington, KJ; Rhys-Evans, P; Archer, DJ; Searle, AE; Henk, JM; Black, CM; (2003) Raynaud's phenomenon after radical radiotherapy for tumours of the head and neck. POSTGRAD MED J , 79 (929) 176 - 177.

Whelan, J; (2003) Studies on cellular sensitivity and resistance to cytosine arabinoside. UNSPECIFIED thesis , UNSPECIFIED.

Whelan, JS; (2003) Working with Adolescents. ESMO Summer Educational Conference, Edinburgh June 2003. In: (pp. 42-).

Whelan, JS; McTiernan, A; (2003) Survival after recurrence of Ewing’s tumour is improved by high dose chemotherapy and surgery. Results of a retrospective analysis of 116 patients. In:

Whelan, JS; O, SC; Stanway, S; Ng, S; (2003) How should glomerular filtration rates be measured in teenagers having chemotherapy? In:

Wilkinson, GP; Loadman, P; Taylor, J; Jenkins, TC; Swaine, D; Double, JA; Spanswick, VJ; ... Thurston, DE; + view all (2003) Pharmacokinetic and intracellular pharmacological characteristics of the novel pyrrolobenzodiazepine (PBD) dimmer SJG-136. In: (pp. 1634-).

Winfield, EA; Deighton, A; Venables, K; Hoskin, PJ; Aird, EGA; (2003) Survey of tangential field planning and dose distribution in the UK: background to the introduction of the quality assurance programme for the START trial in early breast cancer. British Journal of Radiology , 76 (904) pp. 254-259.

Wong, WL; Saunders, M; (2003) The impact of FDG PET on the management of occult primary head and neck tumours. Clinical Oncology , 15 (8) pp. 461-466.

This list was generated on Sun May 20 01:52:53 2018 BST.